Buy the report "Hodgkin, Mantle Cell, Follicular & Natural Killer Cell Lymphoma Therapeutic Review H1 2013" at US $2000 for a Single User PDF License from RnR Market Research Reports Library.

1. RnR Market Research Offers “Hodgkin, Mantle Cell, Follicular & Natural Killer Cell
Lymphoma Therapeutic Review H1 2013” Report at US$ 2000 (Single User License). The
report got published in Feb 2013.
Global Markets Direct’s, ‘Hodgkin, Mantle Cell, Follicular & Natural Killer Cell Lymphoma – Pipeline
Review, H1 2013′, provides an overview of the indication’s therapeutic pipeline. This report provides
information on the therapeutic development for Hodgkin, Mantle Cell, Follicular & Natural Killer Cell
Lymphoma, complete with latest updates, and special features on late-stage and discontinued projects. It
also reviews key players involved in the therapeutic development for Hodgkin, Mantle Cell, Follicular &
Natural Killer Cell Lymphoma. Hodgkin, Mantle Cell, Follicular & Natural Killer Cell Lymphoma – Pipeline
Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary
databases, Company/University websites, SEC filings, investor presentations and featured press releases
from company/university sites and industry-specific third party sources, put together by Global Markets
Direct’s team.
Scope
- A snapshot of the global therapeutic scenario for Hodgkin, Mantle Cell, Follicular & Natural Killer Cell
Lymphoma.
- A review of the Hodgkin, Mantle Cell, Follicular & Natural Killer Cell Lymphoma products under
development by companies and universities/research institutes based on information derived from
company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration
stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Hodgkin, Mantle Cell, Follicular & Natural Killer Cell Lymphoma pipeline on the basis of
route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Get a Report Copy of Natural Killer Cell Lymphomas @ http://www.rnrmarketresearch.com/natural-
killer-cell-lymphomas-pipeline-review-h1-2013-market-report.html
Get a Report Copy of Follicular Lymphomas @ http://www.rnrmarketresearch.com/follicular-
lymphoma-pipeline-review-h1-2013-market-report.html
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Hodgkin,
Mantle Cell, Follicular & Natural Killer Cell Lymphoma.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies
to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Hodgkin, Mantle Cell, Follicular &
Natural Killer Cell Lymphoma pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the
most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that
drove them from pipeline.
Get a Report Copy of Mantle Cell Lymphomas @ http://www.rnrmarketresearch.com/mantle-cell-
lymphoma-pipeline-review-h1-2013-market-report.html

2. Get a Report Copy of Hodgkin @ http://www.rnrmarketresearch.com/hodgkin-lymphoma-pipeline-
review-h1-2013-market-report.html
Table of Content
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Hodgkin Lymphoma Overview 7
Therapeutics Development 8
An Overview of Pipeline Products for Hodgkin Lymphoma 8
Hodgkin Lymphoma Therapeutics under Development by Companies 10
Hodgkin Lymphoma Therapeutics under Investigation by Universities/Institutes 13
Late Stage Products 15
Comparative Analysis 15
Mid Clinical Stage Products 16
Comparative Analysis 16
Early Clinical Stage Products 17
Comparative Analysis 17
Discovery and Pre-Clinical Stage Products 18
Comparative Analysis 18
Hodgkin Lymphoma Therapeutics - Products under Development by Companies 19
Hodgkin Lymphoma Therapeutics - Products under Investigation by Universities/Institutes 21
Companies Involved in Hodgkin Lymphoma Therapeutics Development 23
Seattle Genetics, Inc. 23
Merck & Co., Inc. 24
Gamida Cell Ltd. 25
Infinity Pharmaceuticals, Inc. 26
Plexxikon Inc. 27
Novartis AG 28
Cell Therapeutics, Inc. 29
4SC AG 30
Hana Biosciences, Inc. 31
MethylGene Inc 32
Cytokinetics, Inc 33
Spectrum Pharmaceuticals, Inc. 34
Affimed Therapeutics AG 35
Actinium Pharmaceuticals, Inc. 36
Philogen S.p.A. 37
Stemline Therapeutics, Inc. 38
Syndax Pharmaceuticals, Inc. 39
Xencor, Inc. 40
TaiGen Biotechnology Co., Ltd. 41
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. 42
Lee's Pharmaceutical Holdings Limited 43
Hodgkin Lymphoma - Therapeutics Assessment 44
Assessment by Monotherapy Products 44
Assessment by Combination Products 45
Assessment by Route of Administration 46

3. Assessment by Molecule Type 48
Drug Profiles 51
StemEx - Drug Profile 51
entinostat - Drug Profile 53
pacritinib - Drug Profile 55
brentuximab vedotin - Drug Profile 57
brentuximab vedotin - Drug Profile 60
brentuximab vedotin - Drug Profile 63
mocetinostat - Drug Profile 66
vinorelbine tartrate - Drug Profile 68
panobinostat - Drug Profile 70
everolimus - Drug Profile 73
lucatumumab - Drug Profile 76
4SC-201 - Drug Profile 78
4SC-201 - Drug Profile 82
SB-743921 - Drug Profile 86
SL-101 - Drug Profile 88
pralatrexate - Drug Profile 89
AFM-13 - Drug Profile 92
XmAb-2513 - Drug Profile 93
belinostat + [bortezomib] - Drug Profile 94
clioquinol - Drug Profile 95
bevacizumab + [bleomycin sulfate] + [dacarbazine] + [doxorubucin] + [vinblastine sulfate] - Drug Profile
96
everolimus + panobinostat - Drug Profile 97
Therapeutic allogeneic lymphocytes program - Drug Profile 99
LMP-Specific Cytotoxic T-Lymphocytes - Drug Profile 100
PLX-3397 - Drug Profile 101
TG-0054 - Drug Profile 103
SCH-900776 + [gemcitabine hydrochloride] - Drug Profile 105
galiximab - Drug Profile 106
bortezomib + [filgrastim] + [ifosfamide] + [vinorelbine tartrate] - Drug Profile 107
ofatumumab + [cisplatin] + [cytarabine] + [etoposide] + [methylprednisolone] + Autologous Stem Cell
Transplantation - Drug Profile 108
Autologous CAR.CD30 EBV Specific Cytotoxic T Lymphocytes - Drug Profile 110
Therapeutic tumor infiltrating lymphocytes program - Drug Profile 111
Therapeutic tumor infiltrating lymphocytes program - Drug Profile 113
obinutuzumab + [cyclophosphamide] + [doxorubicin] + [fludarabine] + [prednisone] [INN] + [vincristine] -
Drug Profile 115
LMP Specific Cytotoxic T-Lymphocytes - Drug Profile 118
IPI-145 - Drug Profile 119
LMP-400 - Drug Profile 121
LMP-776 - Drug Profile 123
L19-I131 - Drug Profile 125
JNJ-40346527 - Drug Profile 127
Basiliximab + [Carmustine] + [Etoposide] + [Cytarabine] + [Melphalan] + Autologous Hematopoietic Stem
Cell Transplantation - Drug Profile 128
Allogeneic Donor Derived Lmp Specific Cytotoxic T-Lymphocyte - Drug Profile 129
procarbazine hydrochloride - Drug Profile 130
Iomab-B - Drug Profile 131
Genetically Modified T Cell - Drug Profile 132
Lymphoma Therapy - Drug Profile 133

4. Hodgkin Lymphoma Therapeutics - Drug Profile Updates 134
Hodgkin Lymphoma Therapeutics - Discontinued Products 194
Hodgkin Lymphoma Therapeutics - Dormant Products 195
Hodgkin Lymphoma - Product Development Milestones 198
Featured News & Press Releases 198
Appendix 209
Methodology 209
Coverage 209
Secondary Research 209
Primary Research 209
Expert Panel Validation 209
Contact Us 210
Disclaimer 210
List of Tables
Number of Products Under Development for Hodgkin Lymphoma, H1 2013 12
Products under Development for Hodgkin Lymphoma - Comparative Analysis, H1 2013 13
Number of Products under Development by Companies, H1 2013 15
Number of Products under Development by Companies, H1 2013 (Contd..1) 16
Number of Products under Investigation by Universities/Institutes, H1 2013 18
Comparative Analysis by Late Stage Development, H1 2013 19
Comparative Analysis by Mid Clinical Stage Development, H1 2013 20
Comparative Analysis by Early Clinical Stage Development, H1 2013 21
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013 22
Products under Development by Companies, H1 2013 23
Products under Development by Companies, H1 2013 (Contd..1) 24
Products under Investigation by Universities/Institutes, H1 2013 25
Products under Investigation by Universities/Institutes, H1 2013 (Contd..1) 26
Seattle Genetics, Inc., H1 2013 27
Merck & Co., Inc., H1 2013 28
Gamida Cell Ltd., H1 2013 29
Infinity Pharmaceuticals, Inc., H1 2013 30
Plexxikon Inc., H1 2013 31
Novartis AG, H1 2013 32
Cell Therapeutics, Inc., H1 2013 33
4SC AG, H1 2013 34
Hana Biosciences, Inc., H1 2013 35
MethylGene Inc, H1 2013 36
Cytokinetics, Inc, H1 2013 37
Spectrum Pharmaceuticals, Inc., H1 2013 38
Affimed Therapeutics AG, H1 2013 39
Actinium Pharmaceuticals, Inc., H1 2013 40
Philogen S.p.A., H1 2013 41
Stemline Therapeutics, Inc., H1 2013 42
Syndax Pharmaceuticals, Inc., H1 2013 43
Xencor, Inc., H1 2013 44
TaiGen Biotechnology Co., Ltd., H1 2013 45
Johnson & Johnson Pharmaceutical Research & Development, L.L.C., H1 2013 46
Lee's Pharmaceutical Holdings Limited, H1 2013 47
Assessment by Monotherapy Products, H1 2013 48
Assessment by Combination Products, H1 2013 49
Assessment by Stage and Route of Administration, H1 2013 51

5. Assessment by Stage and Molecule Type, H1 2013 54
Hodgkin Lymphoma Therapeutics - Drug Profile Updates 138
Hodgkin Lymphoma Therapeutics - Discontinued Products 198
Hodgkin Lymphoma Therapeutics - Dormant Products 199
Hodgkin Lymphoma Therapeutics - Dormant Products (Contd..1) 200
Hodgkin Lymphoma Therapeutics - Dormant Products (Contd..2) 201
List of Figures
Number of Products under Development for Hodgkin Lymphoma, H1 2013 12
Products under Development for Hodgkin Lymphoma - Comparative Analysis, H1 2013 13
Products under Development by Companies, H1 2013 14
Products under Investigation by Universities/Institutes, H1 2013 17
Late Stage Products, H1 2013 19
Mid Clinical Stage Products, H1 2013 20
Early Clinical Stage Products, H1 2013 21
Discovery and Pre-Clinical Stage Products, H1 2013 22
Assessment by Monotherapy Products, H1 2013 48
Assessment by Combination Products, H1 2013 49
Assessment by Route of Administration, H1 2013 50
Assessment by Stage and Route of Administration, H1 2013 51
Assessment by Molecule Type, H1 2013 52
Assessment by Stage and Molecule Type, H1 2013 53
For more details contact Mr. Priyank Tiwari: sales@rnrmarketresearch.com / +18883915441
Website: http://www.rnrmarketresearch.com/